FAILURE OF THE HEART DETERMINATION PROTEOMIC PROFILING RELATED TO PATIENTS WHO ARE ELDERLY
Article Sidebar
Main Article Content
Abstract
Objective
These eighty proteins have been identified to be connected with cardiovascular pathology in the past, and the purpose of this study paper is employing proteomic profiling of these proteins in order to discover new risk factors for heart failure or heart failure in general.
Materials and Methods
Analyses of the proximity extension (Proteomic profiling) has been performed in two different communities with varying cohorts in the elderly at the baseline in the absence of cardiac failure. The prospective of the research were Prospective Investigation of the Vasculature (PIV) and Longitudinal Study of Adult Men (LSAM) having respective values (80 events, median age = 70.2 years, n = 901) and (90 events, median age = 77.8 years, n = 685). Incident of heart failure was associated with 29 proteins as observed in PIV with adjusted sex and age. Corrections were made after multiple tests. In LSAM there were 18 proteins associated with heart failure. High level of 9 proteins were related to the incident of heart failure among both the cohorts. There were additional modifications made to the established risk variables. There was a deficit in the left ventricular systolic function that was found to be associated with the presence of growth differentiation factor 15 (GDF-15), urokinase-type plasminogen activator surface receptor (U-PAR), matrix metalloproteinase-12 (MMP-12), tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), spondin-1 (SPON1), and follistatin (FS). This was discovered through echocardiographic monitoring. Each and every one of the P values was lower than 0.02.
Results
The final characteristics of PIV included median age of 70 years among a total of 901 participants. In LSAM the characteristic showed median age of 78 years among 685 participants. During follow-up among PIV the age range was 0.1-10.9 years with a median of 10 years, 80 hospitalizations due to heart failure with a heart failure rate of 0.96 among 100 persons. There were 90 hospitalisations for heart failure among LSAM, the age range was 0.2-10.9 years with a median of 8 years, and the heart failure rate was 1.83 per 100 people. False discovery rate among PIV was 5% with the association of 29 proteins after adjusted sex and age. Among LSAM the association of 18 proteins was nominal for the incident of heart failure.
Conclusion
Several novel associations for the involvement of proteins in fibrinolysis, apoptosis, inflammation, matrix remodeling and heart failure were identified through Proteomic profiling in the research study among elderly. The outcomes of this research also correspond to other investigations that studied underlying clinical utilities and mechanisms.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Arterioscler Thromb Vasc Biol 2005;25:2368–2375. Hedstrand H. A study of middle-aged men with particular reference to risk factors for cardiovascular disease. Ups J Med Sci Suppl 1975; 19:1–61.
Borne Y, Persson M, Melander O, Smith JG, Engstrom G. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. Eur J Heart Fail 2014; 16:377–383.
Clemitson JR, Dixon RJ, Haines S, Bingham AJ, Patel BR, Hall L, Lo M, Sassard J, Charchar FJ, Samani NJ. Genetic dissection of a blood pressure quantitative trait locus on rat chromosome 1 and gene expression analysis identifies SPON1 as a novel candidate hypertension gene. Circ Res 2007;100: 992–999.
Echouffo-Tcheugui JB, Greene SJ, Papadimitriou L, Zannad F, Yancy CW, Gheorghiade M, Butler J. Population risk prediction models for incident heart failure: a systematic review. Circ Heart Fail 2015;8:438–447.
Helske S, Kovanen PT, Lindstedt KA, Lommi J, Turto H, Werkkala K, Kupari M. Increased osteoprotegerin and decreased RANKL associate with the severity of heart failure in patients with aortic stenosis. Circulation 2005; 112: U818–U.
Hong Y, XieW, Chen CS. Effect of shengmai injection on TRAIL death receptor of patients with congestive heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005; 25:1092–1095.
Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study.
Lind L, Ärnlöv J, Lindahl B, Siegbahn A, Sundström J, Ingelsson E. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. Atherosclerosis 2015;242:205–210.
Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 2013;8:1551–1566.
McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J 1998;19 Suppl P: P9–P16.
Willingale R, Jones DJ, Lamb JH, Quinn P, Farmer PB, Ng LL. Searching for biomarkers of heart failure in the mass spectra of blood plasma. Proteomics 2006; 6:5903–5914.
Aslam, I., Asadullah, R. N. A., Akhlaq, F., Ali, A., & Fatima, A. (2023). Diabetic Disease and its 2-4 Fold Mortality Rate, Patients Getting Standard Therapy in the Modern ERA of CVD Risk Reduction. Pakistan Journal of Medical & Health Sciences, 17(01), 420-420.
Rajabboevna, A. R., & Yangiboyevna, N. S. (2023). EPILEPSIYA BILAN OG'RIGAN BEMORLARDA TOPAMAX DORI VOSITASINING KLINIK VA FARMAKOEKONOMIK ASPEKTLARINING SAMARADORLIGINI BAHOLASH. Research Focus International Scientific Journal, 2(5), 198-202.
Jiyanboyevich, Y. S., Aslam, I., Ravshanovna, M. U., Azamatovna, F. G., & Murodovna, J. D. (2021). Ventricular Arrhythmias With Congenital Heart Disease Causing Sudden Death. NVEO-NATURAL VOLATILES & ESSENTIAL OILS Journal| NVEO, 2055-2063.